Stock BBIO BRIDGEBIO PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
28.01 USD -2.91% Intraday chart for BridgeBio Pharma, Inc. +0.25% -30.62%
May. 29 Transcript : BridgeBio Pharma, Inc. - Special Call
May. 28 UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma's Phase 3 ATTRibute-CM Study
Transcript : BridgeBio Pharma, Inc. - Special Call
BridgeBio Pharma : BBIO Acoramidis (AG10) TTR ISA 2024 Featured research in the ATTR CM landscape
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis achieves early reduction in cardiovascular death or hospitalization in transthyretin amyloid cardiomyopathy (ATTR-CM)
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis treatment related increase in serum TTR is associated with lower cardiovascular mortality in ATTR CM
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Higher risk of mortality in previously hospitalized patients
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Early increase in serum transthyretin level is an independent predictor of improved survival in ATTR cardiomyopathy
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Rationale & design of ACT-EARLY
UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
BridgeBio Pharma : BBIO BBP 418 – MENA 2024 – Oral Presentation
Transcript : BridgeBio Pharma, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
BridgeBio Pharma : Bank of America Merrill Lynch Healthcare Conference 2024 Presentation
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ESC Heart Failure 2024 – NT-proBNP Insights from the ATTRibute-CM Study
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ESC Heart Failure 2024 – ITT Sensitivity Analysis and Sub-Analysis Comparing Acoramidis and Placebo in Stage 4 CKD in ATTRibute-CM
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BBIO Stock
  4. News BridgeBio Pharma, Inc.
  5. Other languages